Mycoplasma Testing Market Size Worth $3.14 Billion By 2034,CAGR: 12.03%

The global mycoplasma testing market size is expected to reach USD 3.14 Billion by 2034, according to a new study by Polaris Market Research. The report “Mycoplasma Testing Market Share, Size, Trends, Industry Analysis Report, By Product & Service (Assays, Kits, & Reagents, Instruments, Services); By Technique; By Application; By End User; By Region; Segment Forecast, 2026 - 2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Mycoplasma is a type of bacteria without a cell wall. It is mostly likely to affect the respiratory, urinary, and genital tracts of humans. The presence of stringent regulations and growing concerns about consumer safety is enabling pharmaceutical companies to focus on comprehensive biological testing, including testing of mycoplasma.

The emergence of antimicrobial resistance made it difficult to test the presence of mycoplasma in pharmaceutical products and services, which fueled the development of diagnostic tests to determine resistance. Mycoplasma is mostly found in the production phase of biopharmaceutical products, including from the research stage to clinical development, highlighting the need for mycoplasma testing to check safety and accuracy in treating certain diseases.

The increasing adoption of cell and gene therapies, monoclonal antibodies, vaccines, and other biologics is further strengthening the demand for sensitive mycoplasma testing solutions. Manufacturers are integrating rapid nucleic acid amplification tests and automated detection platforms into quality-control workflows to identify contamination earlier and reduce production delays. These technologies offer improved sensitivity, shorter turnaround times, and greater compatibility with complex biological samples, supporting regulatory compliance and the safe commercialization of biopharmaceutical products.

Mycoplasma Testing Market Report Highlights

• North America led with a 39.0% revenue share in 2025. The presence of a robust healthcare infrastructure contributes to the region’s leading market position.

• Asia Pacific is projected to witness rapid growth at a 13.88% CAGR. This is due to the presence of major players focusing on dependable medicines and therapies.

• The assays, kits, and reagents segment held 57.0% share in 2025. The rising development of new therapies contributes to the segment’s growth.

• The NAT (nucleic acid amplification) segment led with a 26.22% share in 2025. This is owing to the various benefits of NAT.

• The cell line testing segment held a significant market share of 50.0% in 2025. The segment’s dominance is attributed to the continuous rise in the use of cell cultures.

• The global players include American Type Culture Collection; bioMérieux SA; Bionique Testing Laboratories, Inc.; Biotools B & M Labs, S.A.; Charles River Laboratories International, Inc.; Creative Bioarray (US); Eurofins Scientific; GeneCopoeia, Inc.; InvivoGen; Lonza Group Ltd.; Merck KGaA; Minerva Biolabs GmbH; Sartorius AG; SGS S.A.; Thermo Fisher Scientific Inc

Request a free sample copy or read the full market insights :  mycoplasma testing market Report
 

Polaris Market Research has segmented the mycoplasma testing market report based on product & service, technique, application, end user and region:

Mycoplasma Testing, Product & Service Outlook (Revenue - USD Billion, 2021 - 2034)

• Assays, Kits, & Reagents
  • NAT assays, kits, & reagents
  • ELISA assays, kits, & reagents
  • Elimination Kits
  • Stains
  • Other assays, kits, & reagents
• Instruments
• Services

Mycoplasma Testing, Technique Outlook (Revenue - USD Billion, 2021 - 2034)

• NAT
• ELISA
• Staining
• Other technique

Mycoplasma Testing, Application Outlook (Revenue - USD Billion, 2021 - 2034)

• Cell line testing
• Virus Testing
• End-of-Production cell testing

Mycoplasma Testing, End User Outlook (Revenue - USD Billion, 2021 - 2034)

• Pharmaceutical & Biotechnology Companies
• Cell Banks & Laboratories
• Contract Research Organizations
• Academic Research Institutes

Mycoplasma Testing, Regional Outlook (Revenue - USD Billion, 2021 - 2034)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
• Latin America
  • Argentina
  • Brazil
  • Mexico
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Mycoplasma Testing Market Report Scope

Report Attributes	Details
Market size value in 2025	USD 1.13 Billion
Market size value in 2026	USD 1.26 Billion
Revenue forecast in 2034	USD 3.14 Billion
CAGR	12.03% from 2026 – 2034
Base year	2025
Historical data	2021 – 2024
Forecast period	2026 – 2034
Quantitative units	Revenue in USD Billion and CAGR from 2026 to 2034
Segments covered	By Product & Service By Technique By Application By End User By Region
Regional scope	North America Europe Asia Pacific Latin America Middle East & Africa
Competitive Landscape	Mycoplasma Testing Market Share Analysis (2025) Company Profiles/Industry participants profiling includes company overview, financial information, product/service benchmarking, and recent developments
Report Format	PDF + Excel
Customization	Report customization as per your requirements with respect to countries, region and segmentation.
For Specific Research Requirements	Request Customization

Source: Polaris Market Research Analysis